TSM Earnings & $100B U.S. Investment Not Enough for Traders, UNH Rallies

AI memory investors are taking profits in names like SK Hynix and Samsung, a rotation Tom White expects to spill into U.S. tech exposure. TSMC’s earnings added volatility even though it beat expectations, alongside a new $100B planned investment into the U.S. He then shifts to UnitedHealth (UNH), arguing its earnings reflect “correcting the pains” for investors heading into 2025, suggesting mixed near-term sentiment across sectors.

Analysis

Near term, the biggest risk is not the specific earnings prints but the flow regime around semis: profit-taking in AI memory can spill into the entire AI trade because many macro funds still hold it as one crowded factor basket. That tends to hit high-beta names first over 1-3 weeks, even when the underlying end-market is fine, so the cleanest expression is usually to fade memory/PC-levered semis against the rest of the AI infrastructure stack rather than short the whole complex outright.

TSMC’s extra U.S. investment is more important as a supply-chain signal than a direct earnings driver. Over 6-18 months it supports domestic equipment, materials, and specialty chemicals more than the foundry itself, because the incremental capex mostly shifts bargaining power to tools vendors while adding pressure to TSMC’s medium-term margin mix. The market may be overreading it as immediate demand acceleration; in reality it is more about geopolitical redundancy and customer qualification than a sudden step-up in wafer starts.

UNH is the contrarian setup: if management is genuinely normalizing prior operating issues, the market can re-rate the stock well before the next enrollment cycle. The key risk is that any improvement is fragile because managed-care multiples compress quickly when medical cost trends or regulatory noise re-accelerate; that makes this a 1-2 quarter story, not a clean multi-year compounder until utilization data proves stable.

What consensus may be missing is that the current move could be more about rotation than fundamentals: semis are vulnerable to factor de-grossing, while healthcare is getting no credit for mean reversion. If memory pricing or AI capex guidance rolls over, the semiconductor trade can still unwind further; if UNH shows even modest margin stabilization, it can outperform faster than expected because expectations are already depressed.

Key Decisions for Investors

• Short-term hedge: reduce exposure to memory-heavy AI semis and use SOXX/SMH downside as a tactical hedge for the next 1-3 weeks; thesis fails if DRAM/NAND pricing or AI server demand commentary re-accelerates.
• Pair trade over 1-3 months: long AMAT or LRCX vs short memory-beta names / SKHYV-type exposure, since TSMC capex is more supportive for equipment than for foundry margins; cover if capex plans are delayed or tool order momentum softens.
• Small tactical long UNH versus XLV or a managed-care basket (HUM/CNC) for 1-2 quarters, but only if post-earnings revisions stabilize; exit if medical-loss ratio trends or utilization data worsen.
• Alert rather than a conviction trade: if TSM breaks higher on follow-through volume, add selectively to U.S. semiconductor equipment instead of TSM itself, because the capex signal should transmit to suppliers first.
• If memory names underperform for another 5-7 trading days while AI semis hold up, treat that as a rotation signal and rotate away from commodity memory into higher-margin AI compute/infra names.